Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedSep 18, 2025
DataAggregated Company Financials
Companies547
  • 7D-0.4%
  • 3M8.2%
  • 1Y-9.3%
  • YTD5.4%

Over the last 7 days, the Biotech industry has remained flat, although notably AbbVie gained 4.3%. As for the longer term, the industry has declined 9.3% in the last year. Looking forward, earnings are forecast to grow by 26% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 18 Sep 2025US$1.1tUS$163.5b-US$18,382,703,631.6416.1x-57.9x6.5x
Sat, 16 Aug 2025US$1.1tUS$163.6b-US$18,749,403,227.2315.6x-56.7x6.5x
Mon, 14 Jul 2025US$974.6bUS$155.8b-US$23,414,756,764.1818.1x-41.6x6.3x
Wed, 11 Jun 2025US$956.0bUS$155.9b-US$23,940,308,496.7317x-39.9x6.1x
Fri, 09 May 2025US$890.8bUS$155.2b-US$25,508,884,067.7618.2x-34.9x5.7x
Sun, 06 Apr 2025US$735.9bUS$118.6b-US$37,018,260,571.7320.1x-19.9x6.2x
Tue, 04 Mar 2025US$851.9bUS$119.0b-US$37,239,165,117.4618.7x-22.9x7.2x
Thu, 30 Jan 2025US$991.6bUS$149.5b-US$26,328,617,325.6517.4x-37.7x6.6x
Sat, 28 Dec 2024US$987.9bUS$149.9b-US$26,371,086,316.3016.2x-37.5x6.6x
Mon, 25 Nov 2024US$1.0tUS$150.0b-US$26,558,578,256.4416.6x-38.3x6.8x
Wed, 23 Oct 2024US$895.9bUS$113.1b-US$36,020,987,135.8021.4x-24.9x7.9x
Fri, 20 Sep 2024US$919.7bUS$113.2b-US$35,956,842,944.7222.1x-25.6x8.1x
Sun, 18 Aug 2024US$883.1bUS$113.2b-US$35,819,260,655.8322.3x-24.7x7.8x
Tue, 16 Jul 2024US$1.2tUS$164.5b-US$28,103,794,830.8229x-42.5x7.3x
Thu, 13 Jun 2024US$1.2tUS$164.5b-US$28,092,824,135.2828x-41.1x7x
Sat, 11 May 2024US$1.1tUS$164.6b-US$26,942,623,519.8323.3x-41.5x6.8x
Mon, 08 Apr 2024US$1.1tUS$164.4b-US$23,377,298,863.0321.3x-48.3x6.9x
Wed, 06 Mar 2024US$1.2tUS$167.9b-US$21,336,854,000.7816.1x-55.9x7.1x
Fri, 02 Feb 2024US$1.4tUS$204.7b-US$22,768,331,138.0019x-63.6x7.1x
Sun, 31 Dec 2023US$1.4tUS$204.9b-US$22,199,644,413.0019.8x-62.6x6.8x
Tue, 28 Nov 2023US$1.2tUS$204.8b-US$22,010,873,467.0018.7x-55.7x6x
Thu, 26 Oct 2023US$1.2tUS$207.4b-US$13,064,474,784.0016.4x-92.7x5.8x
Sat, 23 Sep 2023US$1.3tUS$207.5b-US$12,879,348,159.0017.1x-97.9x6.1x
Mon, 21 Aug 2023US$1.3tUS$207.6b-US$12,372,676,716.0017.6x-102.2x6.1x
Wed, 19 Jul 2023US$1.1tUS$186.7b-US$15,964,743,132.0012.8x-71.3x6.1x
Fri, 16 Jun 2023US$1.2tUS$186.3b-US$15,880,859,492.0012.2x-72.5x6.2x
Sun, 14 May 2023US$1.2tUS$191.7b-US$12,222,188,637.0013.8x-94.4x6x
Tue, 11 Apr 2023US$1.2tUS$198.2b-US$3,345,249,969.0013.8x-346.3x5.8x
Thu, 09 Mar 2023US$1.1tUS$199.1b-US$4,824,949,147.0015x-232.6x5.6x
Sat, 04 Feb 2023US$1.2tUS$203.6bUS$1.7b15.6x703.6x5.7x
Mon, 02 Jan 2023US$1.2tUS$203.5bUS$1.7b14.3x667.5x5.7x
Wed, 30 Nov 2022US$1.1tUS$202.2bUS$1.3b14.6x876.7x5.5x
Fri, 28 Oct 2022US$1.1tUS$205.5bUS$7.3b14x147.6x5.3x
Sun, 25 Sep 2022US$1.0tUS$206.0bUS$5.6b13.9x182.3x4.9x
Price to Earnings Ratio

182.3x


Total Market Cap: US$1.0tTotal Earnings: US$5.6bTotal Revenue: US$206.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 35.3x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.4% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.17%
Healthcare-0.44%
Biotech-0.36%
Biotech-0.36%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$220.814.3%
+US$16.2b		14.4%PE104.8x
REGN Regeneron PharmaceuticalsUS$585.505.3%
+US$3.1b		-48.6%PE13.6x
ONC BeOne MedicinesUS$332.205.8%
+US$2.0b		68.4%PS8x
ROIV Roivant SciencesUS$15.2811.0%
+US$1.0b		27.3%PS449.1x
NTRA NateraUS$175.433.3%
+US$774.1m		38.0%PS12.3x

Latest News

RVMD
US$43.81
Revolution Medicines
7D
8.3%
1Y
-0.6%
REGN
US$585.50
Regeneron Pharmaceuticals
7D
5.3%
1Y
-48.6%
ROIV
US$15.28
Roivant Sciences
7D
11.0%
1Y
27.3%
CYTK
US$47.56
Cytokinetics
7D
-8.5%
1Y
-15.0%
ABBV
US$220.81
AbbVie
7D
4.3%
1Y
14.4%
BNTX
US$98.15
BioNTech
7D
-2.8%
1Y
-15.1%
EXAS
US$52.38
Exact Sciences
7D
-4.4%
1Y
-24.3%

Humana, Centene And Medicare Coverage Will Increase Screening Access

Analysts have modestly raised Exact Sciences’ price target to $64.01, citing renewed optimism from the Freenome deal and Shield V2 data as potential growth catalysts despite near-term skepticism around CRC blood-test data, resulting in only a slight upward revision to fair value. Analyst Commentary Bullish analysts cite the Freenome deal and Shield V2 data as catalysts for renewed Street focus on execution, with multiple near-term revenue growth drivers, continued EBITDA margin expansion, improving cash flow, and possible estimate upside.
IONS
US$61.17
Ionis Pharmaceuticals
7D
-4.4%
1Y
44.4%
ALNY
US$451.73
Alnylam Pharmaceuticals
7D
-3.7%
1Y
65.4%
ONC
US$332.20
BeOne Medicines
7D
5.8%
1Y
68.4%
AMGN
US$274.71
Amgen
7D
-1.4%
1Y
-17.5%
EXEL
US$40.44
Exelixis
7D
7.3%
1Y
50.8%

Expanding Global Oncology Markets Will Broaden Patient Access

Exelixis’ consensus price target saw a marginal decrease to $44.06 as enthusiasm for positive Phase 3 colorectal cancer trial results and potential new revenue from zanzalintinib was offset by revenue model reductions from the discontinuation of head and neck cancer development and ongoing concerns about long-term growth beyond the Cabometyx 2031 patent expiry. Analyst Commentary Bullish analysts raised price targets due to positive topline results from the STELLAR-303 Phase 3 trial, where zanzalintinib in combination with atezolizumab showed a statistically significant improvement in overall survival in metastatic colorectal cancer, paving the way for potential regulatory approval.
GILD
US$112.26
Gilead Sciences
7D
-2.6%
1Y
33.8%
NTRA
US$175.43
Natera
7D
3.3%
1Y
38.0%

Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities

Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.
SLNO
US$50.98
Soleno Therapeutics
7D
-15.1%
1Y
-4.8%
CRSP
US$59.07
CRISPR Therapeutics
7D
14.0%
1Y
19.1%